GSK plc (NYSE:GSK) and Syndivia on Monday announced an agreement granting GSK exclusive worldwide rights to develop and ...

Under the deal, France-based Syndivia will receive an upfront payment, as well as development and commercial milestone ...

Fresh from a European cancer conference that was all about antibody-drug conjugates (ADCs), GSK has turned to French biotech ...

GSK has boosted its pipeline of antibody-drug conjugates for cancer, licensing a prostate cancer candidate from Syndivia in a ...

London: GSK plc and Syndivia, a private biotechnology company focused on next-generation ADCs, have announced an agreement ...

GSK stock has seen a modest increase in its Fair Value Estimate, climbing from $16.51 to $16.63 per share while the discount ...

--GSK has lately posted lower vaccine sales in China and the U.S., and faces pressure to show that its pipeline includes new blockbuster drugs to counter concerns about that slowdown, AJ Bell ...

Three years after its global market withdrawal and months after a negative advisory committee vote, GSK can officially call it a comeback for its multiple myeloma drug Blenrep in the U.S., albeit w | ...

The antibody-drug conjugate, withdrawn from the market by GSK in 2022 after failing a confirmatory study, was approved ...

GSK's London-listed shares fell about 2% on Friday after the U.S. Food and Drug Administration approved only one of two ...

Walmsley took GSK back into oncology in 2018, after her predecessor Andrew Witty retreated from the specialism in 2015. The ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.